A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 14; no. 5; pp. 968 - 977
• Main Authors: RAGNI, M. V., JANKOWITZ, R. C., CHAPMAN, H. L., MERRICKS, E. P., KLOOS, M. T., DILLOW, A. M., NICHOLS, T. C.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.09.2008
• Subjects: Adult; Deamino Arginine Vasopressin - adverse effects; Deamino Arginine Vasopressin - therapeutic use; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor VIII - metabolism; Female; Hemostatics - adverse effects; Hemostatics - therapeutic use; Humans; Injections, Subcutaneous; Interleukin-11 - administration & dosage; Interleukin-11 - adverse effects; Interleukin-11 - therapeutic use; Male; Platelet Count; Polymerase Chain Reaction - methods; Prospective Studies; recombinant interleukin-11; Recombinant Proteins - therapeutic use; RNA, Messenger - genetics; von Willebrand disease; von Willebrand Diseases - blood; von Willebrand Diseases - drug therapy; von Willebrand factor; von Willebrand Factor - biosynthesis; von Willebrand Factor - genetics; von Willebrand Factor - metabolism; Young Adult

von Willebrand factor (VWF) is a multimeric glycoprotein that mediates platelet adhesion and is decreased in von Willebrand disease (VWD). 1‐8 deamino‐d‐arginine vasopressin (DDAVP), the most common treatment for VWD, is limited by tachyphylaxis and inconvenience, and in 20% of the patients, unrespo...